Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplinalkib in ALK-Positive NSCLC
NCT05801107Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iruplinalkib in anaplastic lymphoma kinase positive non-small cell lung cancer, sponsored by Qilu Pharmaceutical. Primary endpoint: Objective Response Rate at 18 weeks. Status: unknown.
02
Drugs
iruplinalkib
03
Conditions
anaplastic lymphoma kinase positive non-small cell lung cancer
Beyond the preview
Go deeper on NCT05801107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801107.